MGAT2-IN-7 (compound 27Q) is a substituted benzenesulfonamide compound and also a monoacylglycerol acyltransferase 2 (MGAT2) inhibitor. MGAT2-IN-7 is used for research on obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

MG16 is a prodrug of 10-Methoxycamptothecin. MG16 downregulates CDK6 and upregulates ASK1. MG16 induces cell cycle arrest and Apoptosis. MG16 exhibits anticancer activity against Lewis lung carcinoma, small cell lung cancer, and non-small cell lung cancer.

MeV-IN-1 (OX-1) is an inhibitor of specific specific Measles virus (MeV) entry with an IC50 of 100 M. MeV-IN-1 has an IC50 of 55 M against live MeV-Edm. MeV-IN-1 efficiently suppresses the formation of infectious centers. MeV-IN-1 exhibits negligible cytotoxicity. MeV-IN-1 potently suppresses R18 redistribution in MV-H- and MV-F-expressing cells, preventing membrane merging.

METTL3-IN-13 is a METTL3 inhibitor. METTL3-IN-13 is applicable to the research of multiple cancers such as hypopharyngeal squamous cell carcinoma and non-small cell lung cancer.

METTL3-IN-11 is an excellent, selective METTL3 inhibitor (IC50 = 45.31 nM). METTL3-IN-11 exhibits high selectivity towards METTL3 compared to DNMT1, EZH1, MLL1, and PRMT1. METTL3-IN-11 reduces the m6A level of total RNA in MOLM-13 and SKOV3 cells, induces cell apoptosis, and inhibits cell migration. METTL3-IN-11 can reduce the expression of m6A downstream target genes (c-MYC and BCL2). METTL3-IN-11 can be used for the study of ovarian cancer and acute myeloid leukemia.

Methyl threo-12,13-dihydroxy-9(Z)-octadecenoate is a lipid.

Methyl linolenate-13C17 is an isotope-labeled fatty acid ester.

Methyl 8(Z),11(Z),14(Z),17(Z),20(Z)-tricosapentaenoate is an unsaturated fatty acid methyl ester (FAME)。

Methyl 7(E)-nonadecenoate is an unsaturated fatty acid methyl ester (FAME)。

Methyl 6(Z),9(Z),12(Z),15(Z),18(Z)-tetracosapentaenoate is an unsaturated fatty acid methyl ester (FAME)。

Methyl 5-aminovalerate hydrochloride is a PROTAC linker that can be used in the synthesis of PROTACs.

Methyl 3-chlorobicyclo[1.1.1]pentane-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

Methyl 16(Z)-pentacosenoate is a fatty ester.

Methyl 10(Z),13(Z),16(Z)-docosatrienoate is an unsaturated fatty acid methyl ester (FAME)。

Methoctramine is a potent and cardioselectivity antagonist of M2 muscarinic receptor. Methoctramine can inhibit Muscarine-induced bradycardia in vivo. Methoctramine can be used in the study of cardiovascular diseases.

Methiocarb (Mercaptodimethur) is an orally active carbamate insecticide. Methiocarb exerts dose-dependent toxic effects on onions. In addition to inhibiting acetylcholinesterase to induce cholinergic excitation, Methiocarb can induce lipid peroxidation in liver, kidney, brain and testicular tissues and alter reduced glutathione levels by generating ROS. Methiocarb can be used for agricultural pest control and research on oxidative stress-related cellular damage in mammals.

Methetoin is an anticonvulsant.

Mer/c-Met-IN-1 is a potent Mer/c-met dual inhibitor with IC50 values of 1 and 19 nM. Mer/c-Met-IN-1 can inhibit cancer cells proliferation, migration and induce apoptosis. Mer/c-Met-IN-1 can be used for the research of cancer, such as colon cancer.

Menin-MLL-IN-37 is an orally active Menin-MLL protein complex inhibitor with an IC50 of 820.50 nM. Menin-MLL-IN-37 disrupts the interaction between menin and MLL proteins. Menin-MLL-IN-37 induces differentiation of acute myeloid leukemia cells and selectively inhibits the proliferation of MLL-rearranged and DNMT3A/NPM1-mutant leukemia cells. Menin-MLL-IN-37 can be used for the research of acute myeloid leukemia (AML).

Menin-MLL-IN-36 (compound 398) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.043 μM in MEIS1 mRNA expression. Menin-MLL-IN-36 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes.

Menin-MLL-IN-35 (compound 286) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.096 μM in MEIS1 mRNA expression. Menin-MLL-IN-35 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes.

Memagal is an AchE inhibitor (IC50 = 1.16 nM) and a NMDAR antagonist (Ki = 4.6 μM). Memagal inhibits the neurotoxicity induced by NMDA, with its IC50 value being 0.28 nM. Memagal can be used for research on Alzheimer's disease.

Mel56 is a melanogenin analogue. Mel56 can promote the melanin production in human melanoma cells. Mel56 is cytotoxic to cancer cells and induces apoptosis in melanoma cells. Mel56 can be used for the study of melanoma.

MEK-IN-9 (Compound 4-82) is a MEK inhibitor. MEK-IN-9 induces p15 and p27 protein. MEK-IN-9 can be used in the research of renal adenocarcinoma and colorectal cancer.

Meglitinide is an ATP-sensitive potassium (KATP) channel inhibitor. Meglitinide exhibits IC50 values of 0.26 μM, 0.53 μM and 1.6 μM against KATP channels containing SUR1, SUR2A and SUR2B, respectively, with a Kd value of 7 μM for both SUR1 and SUR2A, and a Kd value of 8 μM for SUR2B. Meglitinide binds to the SUR1, SUR2A and SUR2B subunits with high affinity to close KATP channels, acting on a binding site shared by all SUR subtypes, and its interaction with SUR1 carrying the S1237Y mutation remains unchanged. Meglitinide is applicable to research related to type 2 diabetes.

Meayamycin B ((+)-Meayamycin B) is a potent SF3B1 inhibitor. Meayamycin B upregulates the proapoptotic Mcl-1S and downregulates Mcl-1L at the pre-mRNA splicing level. Meayamycin B does not regulate the alternative splicing of Bcl-x. Meayamycin B and ABT-737 synergistically causes Apoptosis. Meayamycin B exhibits anticancer activity against non-small cell lung cancer.

ME-3407 (EF-4040) is a H+-K+-ATPase redistribution disruptor and myosin light chain kinase (MLCK) and protein kinase A inhibitor. ME-3407 blocks gastric acid secretion and aminopyrine accumulation by inhibiting microsomal-to-apical membrane redistribution of H+-K+-ATPase and suppressing MLCK-mediated myosin light chain phosphorylation. ME-3407 is promising for research of peptic ulcer.

MDL-20610 is a potent antirhinovirus compound with an median plaque 50% inhibitory concentrations (IC1/2) of 0.003 µg/mL. MDL-20610 also exhibits activity against human, simian, and bovine rotaviruses and possesses variable enterovirus and paramyxovirus activity. MDL-20610 can be used for antiviral research.

MDL 72832 (hydrochloride) is a 2,3-dihydro-1,4-benzodioxane derivative and a 5-HT1a receptor ligand with high affinity for the 5-HT1a receptor.

MDL 19205 is a cardiotonic agent with inotropic effect. MDL 19205 can be used for the research of cardiovascular disease, such as heart failure.